ALS Clinical Trial Tracker — Monitor the Amyotrophic Lateral Sclerosis Pipeline

Why ALS trial monitoring matters in 2026

Amyotrophic lateral sclerosis (ALS) affects approximately 30,000 Americans and 450,000 people worldwide, with a median survival of 2–5 years from diagnosis. Despite decades of research, only four FDA-approved treatments exist — riluzole, edaravone, sodium phenylbutyrate/taurursodiol, and tofersen. The race for more effective therapies is intensifying.

The ALS trial landscape is now stratified by genetic subtype, creating a more complex competitive matrix:

• SOD1 ALS — tofersen (Biogen) approved 2023; next-gen SOD1-targeting programs and combination strategies now entering trials; represents ~2% of ALS cases but validates the ASO approach
• C9orf72 ALS/FTD — the most common genetic form (~40% of familial ALS); multiple ASO and small molecule programs from Wave Life Sciences, AstraZeneca, and others
• TDP-43 programs — targeting TDP-43 aggregation, mislocalization, and UPS impairment across sporadic and genetic ALS; one of the most active areas in 2026
• FUS ALS — aggressive early-onset form; ION-363 (tofersen successor) in trials
• Sporadic ALS approaches — neuroinflammation, mitochondrial, and glial cell targets for the ~90% of cases without identified genetic cause
• Gene therapy — AAV delivery of protective genes, gene editing approaches from Precision Biosciences and others

What we monitor for ALS

Our daily ClinicalTrials.gov connection can be configured for precise ALS monitoring:

• Condition keywords: "amyotrophic lateral sclerosis", "ALS", "motor neuron disease", "MND", "Lou Gehrig", "progressive muscular atrophy"
• Genetic subtype keywords: "SOD1", "C9orf72", "TDP-43", "TARDBP", "FUS", "UBQLN2", "OPTN", "TBK1" — track any specific subtype
• Mechanism keywords: "antisense oligonucleotide ALS", "ASO motor neuron", "gene therapy ALS", "neuroinflammation ALS"
• Phase filter: Phase 1 (early competitive intelligence), Phase 2/3 (near-term competitive threats)
• Status alerts: New trial registrations, phase progressions, enrollment completions, and study terminations

The antisense oligonucleotide wave in ALS

Tofersen's approval established ASOs as a validated approach in ALS, triggering a wave of follow-on programs. The ASO competitive landscape in ALS in 2026 includes:

• Ionis Pharmaceuticals and its partners with multiple CNS-delivered ASOs in ALS subtypes
• Wave Life Sciences with allele-selective C9orf72 programs
• Multiple academic and industry programs using intrathecal delivery to silence toxic gain-of-function mutations
• New generation of ASOs with improved CNS penetration and dosing intervals entering early trials

For BD teams evaluating platform technologies or pipeline acquisitions in neurodegeneration, tracking ALS ASO trial registrations on ClinicalTrials.gov is a real-time competitive intelligence source.

Who uses ALS trial monitoring

• Neurodegenerative disease BD teams — tracking competitor programs across ALS, FTD, and related motor neuron diseases
• ALS-focused biotech investors — monitoring pipeline milestones and competitive positioning for portfolio companies
• CROs and clinical trial sites — identifying enrollment competition for active ALS studies
• ALS patient advocacy organizations — keeping patients and families informed about available trial options
• Academic neurologists — monitoring the commercial pipeline for investigator-initiated study collaboration opportunities

Pricing

Basic — $49/month: 3 disease/keyword profiles, daily digest, ClinicalTrials.gov monitoring.

Professional — $149/month: Unlimited profiles, phase and sponsor filters, digest frequency options.

Team — $299/month: Everything in Professional for up to 5 users.

All plans include a 14-day free trial. Not charged until day 15.